Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

JOHNSON & JOHNSON

(JNJ)
  Report
Real-time Estimate Cboe BZX  -  10:43 2022-09-27 am EDT
166.20 USD   +0.30%
10:27aLegend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults with Multiple Myeloma
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Johnson & Johnson Announces Executive Changes

08/08/2022 | 06:45pm EDT

Johnson & Johnson announced that Mathai Mammen, M.D., Ph.D., has decided to leave his position as Executive Vice President, Pharmaceuticals, R&D, and pursue other opportunities outside of the company. William Hait, M.D., Ph.D., will serve as interim head of the Pharmaceutical R&D organization until new leadership is identified. Dr. Mammen joined Johnson & Johnson in 2017 as Global Head of Janssen R&D, and the Company thanks Dr. Mammen for his contributions in advancing Johnson & Johnson's portfolio.

The Company will continue to prioritize innovation and building new capabilities to improve the lives of the patients and consumers serve worldwide.


© S&P Capital IQ 2022
All news about JOHNSON & JOHNSON
10:27aLegend Biotech's Cancer Drug Carvykti Gets Japanese Approval to Treat Certain Adults wi..
MT
09/22US Stocks End Lower Thursday Despite Healthcare Gains
MT
09/22US Stocks End Lower Thursday Despite Surge in Healthcare Shares
MT
09/22Johnson & Johnson - Diversifying Our Health Workforce through the Impact of AIM
AQ
09/22Over 200 Inmates, Prison Officers Vaccinated Against Covid-19
AQ
09/21J&J's talc Texas two-step called out by victims
AQ
09/20No, Covid Vaccines Don't Cause Body to Produce Toxic Spike Proteins That Cause Cancer
AQ
09/20Johnson & Johnson Sets Up New R&D Facility in San Francisco Bay Area
MT
09/20Johnson & Johnson Opens State-of-the-Art Science and Technology Campus in San Francisco..
BU
09/20Johnson & Johnson Opens New R&D Facility in San Francisco Bay Area
DJ
More news
Analyst Recommendations on JOHNSON & JOHNSON
More recommendations
Financials (USD)
Sales 2022 95 525 M - -
Net income 2022 22 023 M - -
Net cash 2022 9 791 M - -
P/E ratio 2022 20,3x
Yield 2022 2,64%
Capitalization 436 B 436 B -
EV / Sales 2022 4,46x
EV / Sales 2023 4,18x
Nbr of Employees 141 700
Free-Float 84,2%
Chart JOHNSON & JOHNSON
Duration : Period :
Johnson & Johnson Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends JOHNSON & JOHNSON
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 165,70 $
Average target price 185,07 $
Spread / Average Target 11,7%
EPS Revisions
Managers and Directors
Joaquin Duato Chief Executive Officer & Director
Joseph J. Wolk Chief Financial Officer & Executive Vice President
Matthew Stuckley Senior Financial Analyst-Janssen Commercial Pharm
Alex Gorsky Executive Chairman
Peter Shen Global Head-Research & Development
Sector and Competitors
1st jan.Capi. (M$)
JOHNSON & JOHNSON-3.14%435 655
ELI LILLY AND COMPANY12.76%292 179
ROCHE HOLDING AG-19.31%253 262
ABBVIE INC.4.29%249 673
PFIZER, INC.-25.35%245 989
MERCK & CO., INC.12.45%218 318